Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bergman

Showing results (761-770 of 904) with videos related to

Pageof 91
Sort By:
Endoscopy|December 22, 2012
Prospective feasibility study on the use of multiband mucosectomy for endoscopic resection of early squamous neoplasia in the esophagusY M Zhang, D F Boerwinkel, S He, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2001
Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-IJ M Bergman, M T Abrams, J P Davide, et al.
Gastrointestinal Endoscopy|March 27, 2013
A simplified regimen for focal radiofrequency ablation of Barrett's mucosa: a randomized multicenter trial comparing two ablation regimensFrederike G I van Vilsteren, K Nadine Phoa, Lorenza Alvarez Herrero, et al.
Gut|July 24, 2019
Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre studyAnnieke C G van Baar, Frits Holleman, Laurent Crenier, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|November 30, 2018
A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinomaL C Duits, P Lao-Sirieix, W A Wolf, et al.
Cancer Cell|April 2, 2019
CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate TumorigenesisMichael A Augello, Deli Liu, Lesa D Deonarine, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 21, 2023
A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamideStefan A J Buck, Marinda Meertens, Frederiek M F van Ooijen, et al.
Gut|January 7, 2011
Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trialFrederike G I van Vilsteren, Roos E Pouw, Stefan Seewald, et al.
Journal of the American Chemical Society|July 18, 2001
Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferaseC J Dinsmore, M J Bogusky, J C Culberson, et al.
Gut|July 19, 2014
Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panelLucas C Duits, K Nadine Phoa, Wouter L Curvers, et al.
Pageof 91

Showing results (761-770 of 904) with videos related to

Sort By:
Pageof 91
Endoscopy|December 22, 2012
Prospective feasibility study on the use of multiband mucosectomy for endoscopic resection of early squamous neoplasia in the esophagusY M Zhang, D F Boerwinkel, S He, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2001
Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-IJ M Bergman, M T Abrams, J P Davide, et al.
Gastrointestinal Endoscopy|March 27, 2013
A simplified regimen for focal radiofrequency ablation of Barrett's mucosa: a randomized multicenter trial comparing two ablation regimensFrederike G I van Vilsteren, K Nadine Phoa, Lorenza Alvarez Herrero, et al.
Gut|July 24, 2019
Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre studyAnnieke C G van Baar, Frits Holleman, Laurent Crenier, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|November 30, 2018
A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinomaL C Duits, P Lao-Sirieix, W A Wolf, et al.
Cancer Cell|April 2, 2019
CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate TumorigenesisMichael A Augello, Deli Liu, Lesa D Deonarine, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 21, 2023
A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamideStefan A J Buck, Marinda Meertens, Frederiek M F van Ooijen, et al.
Gut|January 7, 2011
Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trialFrederike G I van Vilsteren, Roos E Pouw, Stefan Seewald, et al.
Journal of the American Chemical Society|July 18, 2001
Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferaseC J Dinsmore, M J Bogusky, J C Culberson, et al.
Gut|July 19, 2014
Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panelLucas C Duits, K Nadine Phoa, Wouter L Curvers, et al.
Pageof 91